Literature DB >> 22172034

The osteoclast and its unique cytoskeleton.

Steven L Teitelbaum1.   

Abstract

The osteoclast cytoskeleton is a unique structure that polarizes the cell's resorptive machinery to the bone-cell interface where it creates an isolated resorptive microenvironment consisting of an actin ring surrounding a ruffled border. This polarization process occurs under the aegis of the α(v) β(3) integrin in collaboration with the M-CSF receptor, c-Fms. When occupied, α(v) β(3) activates a canonical signaling complex consisting of c-Src, Syk, Dap12, Slp76, Vav 3, and Rac that permits the cell to spread and form actin rings. Generation of the ruffled border, the cell's resorptive organelle, is an exocytic process wherein synaptotagmin VII mediates fusion of secretory lysosomes to the bone-apposed plasma membrane. Absence of any component of this signaling pathway compromises osteoclast cytoskeletal organization and abridges bone resorption.
© 2011 New York Academy of Sciences.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22172034     DOI: 10.1111/j.1749-6632.2011.06283.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  62 in total

1.  [Effect of zoledronate on the osteoclast adhesion and gene expression of integrin α(v) and β3].

Authors:  Lin Jueshan; Dong Wei; Xu Chunfeng; Sun Hong; Feng Xiaojie; Qi Mengchun
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2014-12

Review 2.  Regulation of lysosome biogenesis and functions in osteoclasts.

Authors:  Julie Lacombe; Gérard Karsenty; Mathieu Ferron
Journal:  Cell Cycle       Date:  2013-08-05       Impact factor: 4.534

3.  Retinoic acid-induced premature osteoblast-to-preosteocyte transitioning has multiple effects on calvarial development.

Authors:  Shirine Jeradi; Matthias Hammerschmidt
Journal:  Development       Date:  2016-02-22       Impact factor: 6.868

4.  Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation.

Authors:  Lavinia Raimondi; Angela De Luca; Nicola Amodio; Mauro Manno; Samuele Raccosta; Simona Taverna; Daniele Bellavia; Flores Naselli; Simona Fontana; Odessa Schillaci; Roberto Giardino; Milena Fini; Pierfrancesco Tassone; Alessandra Santoro; Giacomo De Leo; Gianluca Giavaresi; Riccardo Alessandro
Journal:  Oncotarget       Date:  2015-05-30

5.  Adaptor protein GRB2 promotes Src tyrosine kinase activation and podosomal organization by protein-tyrosine phosphatase ϵ in osteoclasts.

Authors:  Einat Levy-Apter; Eynat Finkelshtein; Vidyasiri Vemulapalli; Shawn S-C Li; Mark T Bedford; Ari Elson
Journal:  J Biol Chem       Date:  2014-11-07       Impact factor: 5.157

6.  L-Plastin deficiency produces increased trabecular bone due to attenuation of sealing ring formation and osteoclast dysfunction.

Authors:  Meenakshi A Chellaiah; Megan C Moorer; Sunipa Majumdar; Hanan Aljohani; Sharon C Morley; Vanessa Yingling; Joseph P Stains
Journal:  Bone Res       Date:  2020-01-22       Impact factor: 13.567

7.  The dynamin inhibitor dynasore inhibits bone resorption by rapidly disrupting actin rings of osteoclasts.

Authors:  Gnanasagar J Thirukonda; Shunsuke Uehara; Takahiro Nakayama; Teruhito Yamashita; Yukio Nakamura; Toshihide Mizoguchi; Naoyuki Takahashi; Kimitoshi Yagami; Nobuyuki Udagawa; Yasuhiro Kobayashi
Journal:  J Bone Miner Metab       Date:  2015-06-11       Impact factor: 2.626

Review 8.  Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts.

Authors:  Brendan F Boyce
Journal:  J Bone Miner Res       Date:  2013-04       Impact factor: 6.741

Review 9.  Molecular and cellular basis of bone resorption.

Authors:  Reinhard Gruber
Journal:  Wien Med Wochenschr       Date:  2014-09-16

10.  The Cdc42 guanine nucleotide exchange factor FGD6 coordinates cell polarity and endosomal membrane recycling in osteoclasts.

Authors:  Charlotte Steenblock; Tobias Heckel; Cornelia Czupalla; Ana Isabel Espírito Santo; Christian Niehage; Martin Sztacho; Bernard Hoflack
Journal:  J Biol Chem       Date:  2014-05-12       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.